Category Archives: Health Care

Featured, Health Care

Orforglipron vs. Semaglutide: A New Era in Diabetes Treatment

Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

  • For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3
  • In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral semaglutide 14 mg, representing a 73.6% greater relative weight loss
  • Lilly has submitted orforglipron to regulators in over 40 countries, with potential U.S. action for obesity in Q2 2026

INDIANAPOLIS, March 24, 2026 — Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial enrolled 1,698 participants across four treatment arms: orforglipron 12 mg and 36 mg, and oral semaglutide 7 mg and 14 mg. In ACHIEVE-3, orforglipron outperformed oral semaglutide across the primary and all key secondary endpoints, delivering significantly greater improvements in A1C and weight.1,2 The results were published today in The Lancet.

Continue reading Orforglipron vs. Semaglutide: A New Era in Diabetes Treatment →
Health Care

Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss

Dubai, 24 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term. The FDA awarded a Commissioner’s National Priority Voucher for Wegovy® HD, accelerating its review and underscoring its potential to address critical patient needs and national health priorities in the US.

The accelerated approval is based on results from the STEP UP trial programme. In the STEP UP trial, semaglutide 7.2 mg injected once weekly demonstrated 20.7%1 mean weight loss in participants with obesity, and approximately one in three people experienced 25% or greater weight loss. In the STEP UP type 2 diabetes (T2D) trial, in participants with obesity and type 2 diabetes, semaglutide 7.2 mg demonstrated a mean weight loss of 14.1%1. In both trials, the well-known safety and tolerability profile of semaglutide was reaffirmed with semaglutide 7.2 mg, which was comparable to previous trials with semaglutide for weight management.

Continue reading Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss →
Health Care

Breathing slowly into a paper bag can help calm the mind quickly, says an expert

A psychologist provides 5 simple and quick calming techniques to help manage panic and stress.

Simple grounding activities like holding ice, touching textures, walking barefoot, or tuning into surrounding sounds can help anchor the mind in the present and ease panic.

17 March, 2026; Ras Al Khaimah, UAE – In times of uncertainty, continuous exposure to distressing news and information can trigger feelings of stress, anxiety and even sudden panic. Mental health experts say that while such reactions are natural, there are simple techniques individuals can use to regain control of their emotions and calm the mind.

Ms Zobia Amin, Clinical Psychologist, RAK Hospital

Continue reading Breathing slowly into a paper bag can help calm the mind quickly, says an expert →
Health Care, Ramadan Kareem

Friends of Cancer Patients brings together 300 patients and families for Ramadan Iftar in Sharjah

Sharjah, March 12, 2026,

The Friends of Cancer Patients (FOCP) hosted 300 cancer patients and their families at its annual Ramadan Iftar at Al Jawaher Reception and Convention Centre in Sharjah, bringing patients and their loved ones together in an atmosphere of compassion, solidarity and spiritual reflection during the holy month..

The iftar was organised as part of the FOCP’s ongoing efforts to strengthen connections with patients and their families and to reinforce the values of community solidarity during the holy month, with support from IFFCO Group as the event’s sponsor.

Continue reading Friends of Cancer Patients brings together 300 patients and families for Ramadan Iftar in Sharjah →
Health Care

FOCP expands support as global studies highlight mental health impact of cancer

International studies point to high rates of depression and anxiety among cancer patients

Sharjah, March 9, 2026,

When Algerian R.H. began experiencing recurring digestive discomfort and mild bleeding, she assumed it was minor. The 55-year-old UAE resident delayed seeking medical advice. When she eventually did, tests confirmed rectal cancer.

What followed was surgery and treatment. Less visible was the psychological strain that accompanied the diagnosis.

Continue reading FOCP expands support as global studies highlight mental health impact of cancer →